argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Morgan Stanley Positive on argenx SE (ARGX), 'Catalyst Driven Idea: CIDP Topline Readout'
January 5, 2023 4:04 PM ESTMorgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $450.00 price target on argenx SE (NASDAQ: ARGX)
The analyst comments "What and when is the catalyst? Efgartigimod Ph2 ADHERE trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is expected to readout in 1Q23 (NCT04281472). Readout is triggered after 88 relapse events occur in Stage B of the trial. Mgt. plans to report detailed topline data at a later date following the initial press release. The ADHERE trial is designed to test a subcutaneous (subQ) formulation of efgartigimod with a "Go/No-Go" decision... More
